Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma

Cancer

Volumn 110, Issue 11, 2007, Pages 2428-2433

  Hutterer, Georg C ^a,b   Patard, Jean Jacques ^c   Colombel, Marc ^d   Belldegrun, Arie S ^e   Pfister, Christian ^f   Guide, Francois ^c   Artibani, Walter ^g   Montorsi, Francesco ^h   Pantuck, Allan J ^e   Karakiewicz, Pierre I ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c RENNES UNIVERSITY HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HÔPITAL CHARLES NICOLLE   (France)

^g UNIVERSITY OF PADOVA   (Italy)

^h VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Nephrectomy; Nephron sparing surgery; Renal cell carcinoma; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DEMOGRAPHY; FEMALE; HUMAN; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEPHRECTOMY; NEPHRON SPARING SURGERY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEPHRECTOMY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 36448945768     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23054     Document Type: Article

References (10)

1. Dhote R, Pellicer-Coeuret M, Thiounn N, et al. Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. BJU Int. 2000;86:20-27.
2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166:1611-1623.
3. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966-970.
4. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659.
5. Krambeck AE, Leibovich BC, Lohse CM, et al. The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma. J Urol. 2006;176:1990-1995.
6. Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer Staging Manual. 6th ed. New York: Springer; 2002.
7. Patard JJ, Shvarts O, Lam JS, et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol. 2004;171:2181-2185.
8. Negrier S, Gomez F, Douillard JY, et al. Prognostic factors of response or failure of treatment in patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. World J Urol. 2005;23:161-165.
9. Lang H, Lindner V, de Fromont M, et al. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: assessment of 241 patients with >15-year follow-up. Cancer. 2005;103:625-629.
10. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-2540.